Immuron Ltd IMRN
Immuron Ltd (Nasdaq: IMRN) is an infectious disease drug developer. Its lead program, Travelan (IMM-124E), is in Phase 2 for Prevention of travelers' diarrhea (ETEC). Its next catalyst on record is Travelan: End-of-Phase 2 meeting with FDA on pivotal Phase 3 / BLA strategy (date not stated).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Travelan — End-of-Phase 2 meeting with FDA on pivotal Phase 3 / BLA strategy (date not stated). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Travelan (IMM-124E), oral polyclonal bovine antibody | Travelers' diarrhea prophylaxis (BLA path planned) | antibody | Phase 2 |
| IMM-529 | Clostridioides difficile infection / recurrent CDI | antibody | Pre-clinical |
| ProIBS (marketed in Australia as listed medicine/medical device) | IBS symptom relief | unclear | NA_NON_THERAPEUTIC |
Recent results and decisions
- Dec 10, 2025missed USU-run P2TD trial of third-party-made IMM-124E (600 mg twice daily) missed its primary endpoint; Immuron says dosing differed from Travelan directions and will propose 3x daily at End-of-Phase 2.
Primary Endpoint did not reach statistical significance
Filing - Nov 5, 2025n/a FDA allowed IMM-529 IND (IND 32095) to proceed for Phase 2 in CDI.
the United States Food and Drug Administration (FDA) has approved Immuron’s Investigational New Drug application for IMM-529 and the Phase 2 clinical trial may proceed
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 infectious disease companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.